Published in J Urol on November 01, 2001
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
Targeted therapy in renal cell carcinoma. World J Urol (2008) 1.56
Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. JAMA Oncol (2015) 1.51
Percutaneous ablation in the kidney. Radiology (2011) 1.51
Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol (2011) 1.46
Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res (2010) 1.25
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res (2011) 1.21
UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer (2009) 1.18
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol (2010) 1.08
Multivariate analysis of the factors involved in loss of renal differential function after laparoscopic partial nephrectomy: a role for warm ischemia time. Can Urol Assoc J (2011) 1.08
Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study. Oncol Lett (2012) 1.05
Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation. Indian J Med Res (2014) 1.04
Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J (2008) 1.03
Axitinib for the management of metastatic renal cell carcinoma. Drugs R D (2011) 1.01
Management of renal tumors by image-guided radiofrequency ablation: experience in 105 tumors. Cardiovasc Intervent Radiol (2007) 1.01
Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget (2015) 1.00
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene (2010) 0.99
Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res (2011) 0.98
Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther (2012) 0.97
Percutaneous biopsy for risk stratification of renal masses. Ther Adv Urol (2015) 0.97
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun (2007) 0.96
Volume doubling time and growth rate of renal cell carcinoma determined by helical CT: a single-institution experience. Eur Radiol (2007) 0.95
Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol (2015) 0.95
Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007. Cancer Causes Control (2014) 0.95
Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol (2012) 0.94
Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res (2016) 0.94
Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol (2006) 0.93
Metastatic tumors to the pancreas: The role of surgery. World J Gastrointest Oncol (2014) 0.92
Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol (2014) 0.92
Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. Dis Markers (2014) 0.92
Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis. Mol Cell Proteomics (2009) 0.92
Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol (2015) 0.92
Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway. Mol Cancer (2014) 0.91
The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma. J Urol (2012) 0.91
Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma. J Manag Care Pharm (2011) 0.90
Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int (2013) 0.90
Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol (2007) 0.90
Prognostic prediction and diagnostic role of intercellular adhesion molecule-1 (ICAM1) expression in clear cell renal cell carcinoma. J Mol Histol (2014) 0.90
The complex roles of Wnt antagonists in RCC. Nat Rev Urol (2011) 0.89
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol (2005) 0.89
Value of the diffusion-weighted MRI in the differential diagnostics of malignant and benign kidney neoplasms - our clinical experience. Pol J Radiol (2014) 0.89
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med (2011) 0.88
Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci (2005) 0.88
Tumor doubling time of renal cell carcinoma measured by CT. Indian J Urol (2014) 0.88
Computed tomography and magnetic resonance imaging appearance of renal neoplasms after radiofrequency ablation and cryoablation. Semin Ultrasound CT MR (2009) 0.88
Future direction of renal positron emission tomography. Semin Nucl Med (2006) 0.87
The Prognostic Factors for Patients with pT1a Renal Cell Carcinoma. Korean J Urol (2010) 0.87
Key clinical issues in renal cancer: a challenge for proteomics. World J Urol (2007) 0.87
Staging of renal cell carcinoma: Current concepts. Indian J Urol (2009) 0.86
The Relationship between B7-H4 Expression and Clinicopathological Characteristics in Clinical Stage T1 Conventional Renal Cell Carcinoma. Korean J Urol (2011) 0.86
Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors. Nat Rev Urol (2010) 0.85
Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther (2009) 0.85
Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade. Urology (2013) 0.85
Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging (2007) 0.84
Immunotherapy in metastatic renal cell carcinoma. World J Urol (2005) 0.84
A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J (2008) 0.84
Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol (2007) 0.84
Metastatic renal cell carcinoma without evidence of a primary renal tumour. Curr Oncol (2014) 0.84
Renal cell carcinoma with secondary hemophagocytic syndrome: A case report. Can Urol Assoc J (2012) 0.83
Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients. Crit Rev Oncol Hematol (2008) 0.83
Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma. J Exp Clin Cancer Res (2010) 0.83
Implications of computer tomography measurement in the management of renal tumours. BMC Urol (2008) 0.83
Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br J Cancer (2006) 0.82
Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol (2013) 0.82
High expression of long non-coding RNA lncRNA-ATB is correlated with metastases and promotes cell migration and invasion in renal cell carcinoma. Jpn J Clin Oncol (2016) 0.82
8-year survival in a patient with several recurrences of renal cell carcinoma after radical nephrectomy. Cent European J Urol (2012) 0.82
Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J (2009) 0.82
The 1,318-nm diode laser supported partial nephrectomy in laparoscopic and open surgery: preliminary results of a prospective feasibility study. Lasers Med Sci (2011) 0.81
Pancreatic metastases from renal cell carcinoma: a case report and literature review of the clinical and radiological characteristics. World J Surg Oncol (2013) 0.81
Aqueous Extract of Paeonia suffruticosa Inhibits Migration and Metastasis of Renal Cell Carcinoma Cells via Suppressing VEGFR-3 Pathway. Evid Based Complement Alternat Med (2012) 0.81
The current role of lymph node dissection in the management of renal cell carcinoma. Int J Surg Oncol (2011) 0.81
New tools for assessing the individual risk of metastasis in renal cell carcinoma. Clin Exp Metastasis (2012) 0.81
Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol (2010) 0.81
Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer. Mayo Clin Proc (2015) 0.81
Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res Clin Oncol (2005) 0.80
Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Rev Urol (2002) 0.79
Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway. PLoS One (2011) 0.79
Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma. Biomed Res Int (2015) 0.79
High-intensity focused ultrasound in small renal masses. Adv Urol (2008) 0.79
Cryoablation for small renal masses. Adv Urol (2008) 0.79
Surveillance as an option for the treatment of small renal masses. Adv Urol (2008) 0.79
Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma. World J Surg Oncol (2014) 0.78
An overview of image-guided percutaneous ablation of renal tumors. Semin Intervent Radiol (2010) 0.78
Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. Can Urol Assoc J (2009) 0.78
Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol (2010) 0.78
Complications of radical nephrectomy for renal cell carcinoma: a retrospective study comparing transperitoneal and retroperitoneal approaches using a standardized reporting methodology in two Chinese centers. Chin J Cancer (2013) 0.78
IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother (2014) 0.78
Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials. Clin Genitourin Cancer (2014) 0.78
MicroRNA-497 suppress renal cell carcinoma by targeting VEGFR-2 in ACHN cells. Biosci Rep (2017) 0.77
Metastasis of renal cell carcinoma to the parathyroid gland 16 years after radical nephrectomy: A case report. Oncol Lett (2016) 0.77
Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma. J Cancer Res Clin Oncol (2015) 0.77
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access J Urol (2011) 0.77
Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma. J Oncol (2012) 0.77
Screening for kidney cancer: is there a role for aquaporin-1 and adipophilin? Mayo Clin Proc (2010) 0.77
The impact of renal tumor size on the efficacy of laparoscopic renal cryoablation. Korean J Urol (2010) 0.77
The Choi response criteria for inferior vena cava tumor thrombus in renal cell carcinoma treated with targeted therapy. J Cancer Res Clin Oncol (2014) 0.77
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest (2001) 2.01
A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes (2000) 1.55
Cryosurgical ablation for prostate cancer: preliminary results of a new advanced technique. Isr Med Assoc J (2001) 1.42
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med (2001) 1.29
Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol (2000) 1.27
Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am (2000) 1.17
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15
Incidental renal tumors. Urology (2000) 1.11
Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology (2001) 1.05
Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res (1997) 1.04
Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther (1995) 0.95
Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int (2004) 0.94
CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol (2000) 0.93
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res (2001) 0.92
Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol (2001) 0.89
Biology of renal cell carcinoma: changing concepts in classification and staging. Semin Urol Oncol (2001) 0.89
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest (1996) 0.89
Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother (2001) 0.87
Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. J Urol (1997) 0.87
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther (2001) 0.85
In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer (1996) 0.85
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol (2001) 0.84
Prognostic factors and molecular markers for renal cell carcinoma. Expert Rev Anticancer Ther (2001) 0.84
Survey of symptoms following intake of pyridostigmine during the Persian Gulf war. Isr J Med Sci (1992) 0.84
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol (2001) 0.82
Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4. J Immunother (1991) (1992) 0.80
Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications. Hum Gene Ther (1992) 0.79
Immunotherapy of prostate cancer. Curr Urol Rep (2001) 0.79
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. Evid Based Complement Alternat Med (2013) 0.78
The role of endoscopic retrograde cholangiopancreatography in management of patients recovering from acute biliary pancreatitis in the laparoscopic era. Surg Endosc (1997) 0.78
The utility of PSA doubling time to monitor prostate cancer recurrence. Mayo Clin Proc (2001) 0.77
Laparoscopic radical nephrectomy. Semin Urol Oncol (2001) 0.77
Interferon alpha for the treatment of superficial bladder cancer. Adv Exp Med Biol (1999) 0.77
Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology (2009) 0.76
Dendritic cell-based immunotherapy of renal cell carcinoma. Curr Urol Rep (2001) 0.76
Rethinking staging and treatment for renal cell cancer. Rev Urol (2001) 0.75
Biomarkers for early detection and optimized treatment for transitional cell carcinoma. Rev Urol (2001) 0.75
Molecular markers for renal cell carcinoma. Rev Urol (2000) 0.75
Interferon and kidney cancer: a promise unfulfilled? Cancer J Sci Am (1998) 0.75
Immune and genetic therapies for advanced renal cell carcinoma. Rev Urol (2000) 0.75
Determining the optimal treatment for advanced bladder cancer. Rev Urol (2001) 0.75
Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas. Rev Urol (2000) 0.75
Gene and immune therapy for renal cell carcinoma. Int J Urol (2001) 0.75
New algorithms for the staging of kidney cancer. Cancer Treat Res (2003) 0.75
Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br J Urol (1997) 0.75
Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer. Curr Urol Rep (2001) 0.75
[The etiology of benign prostatic hyperplasia--recent findings]. Harefuah (1999) 0.75
Ureteral catheterization and patient mobilization: is bed restriction mandatory? Eur Urol (1999) 0.75
New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions. Urology (2001) 0.75
[Percutaneous choledochoscopic electrohydraulic lithotripsy]. Harefuah (1996) 0.75
[Laparoscopic radical prostatectomy for prostate cancer--a trend or a surgical anecdote?]. Harefuah (2001) 0.75
A genetic sequence change in the 3'-noncoding region of the androgen receptor gene in prostate carcinoma. Eur Urol (1997) 0.75
[Radical prostatectomy]. Harefuah (1992) 0.75
Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol (2001) 0.75
[Transrectal ultrasound-controlled needle aspiration of a prostatic cyst]. Harefuah (1996) 0.75
Molecular-based therapies for renal cell carcinoma. Curr Urol Rep (2001) 0.75
Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions. World J Urol (2000) 0.75
Factors affecting tube dwelling time after percutaneous nephrolithotomy. J Endourol (2001) 0.75
Metabolic effects of thiazide and 1,25-(OH)2 vitamin D in postmenopausal osteoporosis. Osteoporos Int (1993) 0.75
[Obstruction of the prostatic urethra by villous adenoma]. Harefuah (1994) 0.75
[Carcinoma of the prostate--the dilemma increases]. Harefuah (1995) 0.75
Towards kidney cancer crystal ball. Better prognostication of patients with renal cell carcinoma. J Urol (2001) 0.75
[Cryosurgery in prostate cancer]. Harefuah (2001) 0.75
[Incomplete penile amputation: diagnostic and therapeutic challenge]. Harefuah (1997) 0.75
Gene therapy for prostate cancer. New perspectives on an old problem. Urol Clin North Am (1999) 0.75
[BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder]. Harefuah (1999) 0.75
Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association. Rev Urol (2001) 0.75